Featuring: STPs and Pharma; AI in R&D; Secondary patent battles
Sustainability and Transformation Plans (STPs) are set to create upheaval in the NHS – and in the pharma industry too
PharmaTimes speaks to AI expert Jackie Hunter about the future of these technologies in R&D
The European Commission has ruled that UCB’s anti-epileptic Vimpat can be used in children.
22nd September 2017
The National Institute for Health and Care Excellence (NICE) has issued a final positive recommendation for Bayer’s Eylea as a treatment for adults for the treatment of visual impairment due to myopic chorodial neovascularisation.
22nd September 2017
Some patients with rheumatoid arthritis living in England and Wales should get ‘routine’ NHS access to Sanofi’s Kevzara after cost regulators issued draft guidelines deeming the drug cost effective.
22nd September 2017
US regulators have issued a safety communication warning of the risk for serious liver injury and death from incorrect dosing of Intercept Pharmaceuticals' Ocaliva in patients with primary biliary cholangitis.
22nd September 2017
The Awards Ceremony for Marketer & Communications Team of the Year will take place at the London Marriott Hotel, Grosvenor Square on Thursday 9 November.
21st September 2017
Why UK expats in former British colonies are not missing the NHS
Why life sciences shouldn't overlook UX
Joseph B. Laudano, vice president, medical affairs strategy for Medmeme, takes a look at advances in data mining and metrics analysis
In a world of increasingly complex pharma supply chains, technology is playing a growing role in helping smooth the relationship between businesses and their suppliers
How to become investigator sites’ payments sponsor of choice
How targeted digital advertising could help pharma marketers avoid some of the industry’s most common pitfalls
Paul Midgley, director of NHS Insight at Wilmington Healthcare, explains how Capped Expenditure Processes (CEP) will impact both NHS services and pharma sales
Inside the technological, legislative and financial checks on the rise of genome-based medicine
Jaak Peeters, head of Johnson & Johnson Global Public Health, on pharma’s role in supporting global health, fighting epidemics and making medicines accessible
The unusual circumstances of Fujifilm and AbbVie’s Humira patent case and its potential impacts on the market
The NHS scores better than many other countries in terms of access to health – until you take outcomes into account
PharmaTimes speaks to AI expert Jackie Hunter about the future of these technologies in R&D
Biologic drugs are big. A heterogeneous mixture of more than 1,300 weighty amino acids, they are hundreds of times the 1- to 2 ml size of conventional small molecule injectables. That renders them hard to make - and even harder for patients to take.
Jeff Zucker of Worldwide Clinical Trials explains the key to improving study site performance
When we ignore carers, we miss out on one of our best shots at driving treatment success, says David Hunt, CEO of Havas Lynx
Across all industries, people are changing the ways they engage with products, services, and brands. View more...
Wednesday, 28 September 2016 - 11:00 am
George Underwood
FREE - Listen again now - | VIEW NOW
